2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients
Background: The incidence and consequences of de novo donor-specific anti-HLA antibodies (DSAs) after liver transplantation (LT) are not well known. Thus, we investigated the incidence,…2015 American Transplant Congress
Gene Expression Monitoring in Pediatric Heart Transplant Recipients
Allomap® gene expression testing is a non-invasive screening tool approved for use in heart transplant recipients age 15 and older. Experience with Allomap® in pediatric…2015 American Transplant Congress
Clinical Significance of Estimated DSA MFI Values at 1,000 C1q MFI for Differentiation Between Harmful and Harmless DSA
INTRODUCTIONControl of chronic antibody mediated rejection (CAMR) is essential for further improvement of long-term graft survival. Early detection of de novo donor specific antibodies (DSA)…2015 American Transplant Congress
Belatacept in a Community Hospital Adult Kidney Transplant Program
Iowa Methodist Medical Center, Des Moines, IA.
PURPOSE:This is a retrospective look (08/2011-11/2014) on data collected from patients transplanted at Iowa Methodist Transplant Center.METHODS:All patients were EBV positive. They were induced with…2015 American Transplant Congress
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation
Background: The first year after cardiac transplantation is critical for transplant survival and long-term outcome. Identification of suitable biomarkers for detection of rejection processes is…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Risk Factors for Acute Cellular Rejection for Pediatric Kidney Transplant Recipients
Background: Acute cellular rejection (ACR) potentially shortens the life of a kidney allograft. We sought to determine risk factors associated with the development of ACR…2015 American Transplant Congress
Multicenter Validation of a Molecular Diagnostic for Antibody-Mediated Rejection in Formalin-Fixed Paraffin-Embedded Human Renal Allograft Biopsies
1University of Alberta, Edmonton, Canada; 2Imperial College, London, United Kingdom.
Background: In 2013, the Banff classification adopted molecular diagnostics as an adjunct for the diagnosis of antibody-mediated rejection (ABMR) in renal allografts. The NanoString gene…2015 American Transplant Congress
Urinary CXCL10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection
The urinary levels of CXCL9 and CXCL10 can noninvasively diagnose T cell-mediated rejection (TCMR) of renal allografts. Their performance as diagnostic/prognostic markers of antibody-mediated rejection…
American Transplant Congress abstracts